Structure Therapeutics Inc (GPCR)
41.14
-0.01
(-0.02%)
USD |
NASDAQ |
Nov 01, 16:00
41.17
+0.03
(+0.07%)
After-Hours: 20:00
Structure Therapeutics Enterprise Value: 1.426B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 1.426B |
| October 31, 2024 | 1.427B |
| October 30, 2024 | 1.238B |
| October 29, 2024 | 1.306B |
| October 28, 2024 | 1.214B |
| October 25, 2024 | 1.223B |
| October 24, 2024 | 1.215B |
| October 23, 2024 | 1.250B |
| October 22, 2024 | 1.327B |
| October 21, 2024 | 1.293B |
| October 18, 2024 | 1.332B |
| October 17, 2024 | 1.339B |
| October 16, 2024 | 1.303B |
| October 15, 2024 | 1.149B |
| October 14, 2024 | 1.167B |
| October 11, 2024 | 1.265B |
| October 10, 2024 | 1.296B |
| October 09, 2024 | 1.377B |
| October 08, 2024 | 1.389B |
| October 07, 2024 | 1.382B |
| October 04, 2024 | 1.532B |
| October 03, 2024 | 1.492B |
| October 02, 2024 | 1.560B |
| October 01, 2024 | 1.486B |
| September 30, 2024 | 1.583B |
| Date | Value |
|---|---|
| September 27, 2024 | 1.461B |
| September 26, 2024 | 1.448B |
| September 25, 2024 | 1.472B |
| September 24, 2024 | 1.591B |
| September 23, 2024 | 1.495B |
| September 20, 2024 | 1.471B |
| September 19, 2024 | 1.289B |
| September 18, 2024 | 1.261B |
| September 17, 2024 | 1.272B |
| September 16, 2024 | 1.361B |
| September 13, 2024 | 1.409B |
| September 12, 2024 | 1.377B |
| September 11, 2024 | 1.340B |
| September 10, 2024 | 1.042B |
| September 09, 2024 | 1.087B |
| September 06, 2024 | 1.186B |
| September 05, 2024 | 1.268B |
| September 04, 2024 | 1.239B |
| September 03, 2024 | 1.256B |
| August 30, 2024 | 1.254B |
| August 29, 2024 | 1.265B |
| August 28, 2024 | 1.324B |
| August 27, 2024 | 1.422B |
| August 26, 2024 | 1.395B |
| August 23, 2024 | 1.349B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
620.89M
Minimum
May 18 2023
3.241B
Maximum
Oct 31 2023
1.413B
Average
1.292B
Median
Apr 17 2024
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.191B |
| Eli Lilly and Co | 805.11B |
| Novo Nordisk AS | 497.34B |
| Pfizer Inc | 221.03B |
| Amgen Inc | 222.98B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.03M |
| Total Expenses (Quarterly) | 33.32M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -5.40% |